Sign in
THRX Stock Price, Chart, Stats & News
Theseus Pharmaceuticals, Inc.
Save
Theseus Pharmaceuticals, Inc. (THRX) does not currently pay a dividend.
181.50M
Market cap
–
Current P/E
–
Forward P/E
THRX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 6.97% |
ROA | -21.16% |
ROE | -20.74% |
D/E | 0.02x |
Interest coverage ratio | – |
THRX valuation
P/E | – |
P/S | – |
P/B | 0.75x |
P/CF | -4.75x |
P/FCF | -5.43x |
P/OCF | -4.75x |
PEG | -0.03x |
EV multiple | -5.03x |
About
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market targeted treatments for cancer patients. Their leading investigational compound, THE-630, is a pan-KIT inhibitor undergoing Phase I clinical trials for treating gastrointestinal stromal tumors. The company is also advancing a fourth-generation EGFR inhibitor specifically designed to combat the C797S EGFR mutation, which confers resistance to initial or later-line osimertinib therapy in individuals with non-small cell lung cancer.
Similar securities
Based on sector and market capitalization
Report issue